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Summary
Objective To analyze the drug adherence rates and
overall survival for in patients treated with arbiraterone
acetate (AA) for castration-resistant prostate cancer
(CRPC).
Methods The database of the largest insurance com-
pany in Austria (Wiener Gebietskrankenkasse) was an-
alyzed. Data on all CRPC patients with at least one
prescription of AA between November 2011 and De-
cember 2014 in the postchemotherapy setting were
collated and compared to the Austrian death and hos-
pital admission statistics. Drug adherence was esti-
mated by the medication possession ratio (MPR).
Results Data of 270 patients (mean age 73.5 ±
8.9 years) were analyzed. The mean duration of AA
treatment was 9.8 months (range 1–38 months). The
duration of AA treatment was as follows: 0–2 months
53 patients (19.6%), 3–5 months 73 patients (28.1%),
6–10 months 67 patients (24.8%) and >10 months 97
patients (35.9%). The median MPR was 100% and in
241 (89.2%) the MPR exceeded ≥80%. The median
overall survival (OS) was 11months. Based on Kaplan-
Meier analysis, the 6 month OS was 61%, 12 month
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OS 43%, 18 month OS 35% and >24 month OS 24%.
The OS was strongly correlated to patient age and the
duration of AA treatment. Of all 270 patients, only
19 (7%) were not hospitalized during their remaining
life span and 71 (26.2%) spent more than 50% of their
remaining life span in hospital care.
Conclusion The OS was shorter than in phase III trials
and strongly correlated to patient age and the dura-
tion of AA treatment. The high mortality rate within
the first 6 months of AA treatment in this real-life set-
ting suggests a less stringent patient selection than in
a phase III trial.
Keywords Medication adherence · Prostate cancer ·
Abiraterone acetate · Castration-resistant prostate
cancer · Survival
Introduction
In the past 15 years oral anticancer medications have
become more widely available for the treatment of
a variety of cancers and have increasingly been used
as an alternative to intravenous (iv) therapy. This
trend is also demonstrable in the management of ad-
vanced prostate cancer (PC). The introduction of the
oral drugs abiraterone acetate (AA) and enzalutamide
[1] has revolutionized the management of castration
resistant prostate cancer (CRPC). The availability of
oral anticancer drugs aligns with the preferences of
cancer patients andmay help to improve patient qual-
ity of life and reduce the time spent in healthcare
settings; however, the availability of oral drugs in-
duces the issue of drug compliance or adherence [2,
3]. Both terms define the extent to which patients
take medications as prescribed by their healthcare
providers. Without adequate adherence, the efficacy
of oral drugs might fall below of those administered
intravenously. The second threat of an oral drug, par-
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Table 1 Medicationpossession ratio
Medication possession ratio
Mean Median
Total patients (n = 270) 94.8 ± 11.9 100
Age 46–60 (years, n = 19) 94.9 ± 12.2 100
Age 61–70 (years, n = 80) 95.7 ± 12.1 100
Age 71–80 (years, n = 105) 95 ± 10.7 100
Age 81–92 (years, n = 66) 93.5 ± 13.6 100
ticularly if well tolerated such as AA and enzalutamide,
is that these drugs might be prescribed too liberally.
Prompted by the paucity of data of both aspects we
investigated these issues by analyzing the database of
the largest public health insurance in Austria (Wiener
Gebietskrankenkasse, WGKK). This database was
compared to the Austria death statistics and hos-
pital admission registry. For decades Austria has had
a public healthcare system with compulsory state in-
surance. The high prevalence of CRPC as well as the
cost of these drugs further emphasize the economic
impact of drug adherence and prescription pattern.
The aim of this study was to evaluate (i) adherence
patterns for AA and concomitant prednisone in pa-
tients with CRPC in Austria, (ii) the overall survival of
CRPC receiving AA in a real-life setting and (iii) hos-
pital admission rates in this cohort by using a large
administrative healthcare database.
Material and methods
After receiving institutional board approval from our
hospital the prescription database of the largest pub-
lic insurance company in Austria the WGKK was re-
viewed. Data from all patients with at least one pre-
scription of AA from November 2011 to December
2014 were extracted, where AA [1] is typically pre-
scribed at 1000 mg daily taken orally with 10 mg oral
prednisone. The following data were extracted from
this database: age, data of the first AA prescription,
number of AA prescriptions, number of hospital ad-
missions and duration of hospital admissions. This
database was matched to the Austria death and hos-
pital admission statistics.
Adherence [2, 3] was calculated using the medica-
tion possession ratio (MPR), which is the sum of all
days of AA supplied within a given period, divided
by the total number of days in that period. There is
no consensus standard for what constitutes adequate
adherence. Some trials consider rates of greater than
80% to be acceptable [4, 5].
Statistical analyses
The SPSS 17.0 package for Windows (SPSS, Chicago,
IL) was used for statistical analysis and all the values
were expressed in terms of means ± SD for the efficacy
analysis. Survival time was calculated from the initia-
tion of AA and the date of death. Patients alive were
censored at the last known follow-up date. Overall
survival (OS) rates were estimated using the Kaplan-
Meier method.
Results
Patient characteristics and AA prescription pattern
Data of 270 patients with CRPC with at least 1 pre-
scription of AA were analyzed. The mean patient age
was 73.5 ± 8.3 years (median 74 years). The age distri-
bution was as follows: ≤60 years 19 patients (7.0%),
61–70 years 82 patients (30.4%), 71–80 years 105 pa-
tients (38.9%) and >80 years 66 patients (24.4%). The
mean duration of AA treatment in all patients was
9.5 months (range 1–38 months). The duration of
AA treatment was as follows: 0–2 months 53 (19.6%),
3–5 months 73 (28.1%), 6–10 months 67 (24.8%) and
>10 months 97 (35.9%).
Drug adherence
The mean MPR was 94.8 ± 11.9 with a median value
of 100%. The mean MPR ranged from 40–100%. The
MPR was not dependent on patient age (Table 1). In
the age group ≤70 years the meanMPRwas 95.7 ± 12.1
as compared to 95 ± 10.7 in those older than 70 years.
In 241 (89.3%) patients the MPR was ≥80% and the
MPR was below the critical value of 80% only in 29
(10.7%) patients.
Survival
The mean OS was 15.7 ± 1.1 months (median
11 months) with a range of 1–38 months (Fig. 1a).
According to Kaplan-Meier analysis, the 6 month OS
was 61%, the 12 month OS 43%, the 18 month OS
35% and the 24 month OS 24%. One quarter of
patients survived longer than 2 years (Fig. 1a). Pa-
tient age had a profound impact on OS (Fig. 2). At
18 month follow-up, 42% of the younger age cohort
(median age 69.5 years) were still alive as compared to
only 19% in the elderly cohort (median age 83 years)
(Fig. 2). It is worth noting that 35% of all patients in
the younger cohort experienced a survival of longer
than 2 years. The median OS in the younger cohort
was 17 months (mean 19.1 ± 1.4 months) as compared
to only 5 months (mean 8.8 ± 1.0 months) in the el-
derly cohort. Fig. 3 presents the OS depending on
the length of AA treatment and OS was also strongly
dependent on the duration of AA treatment (Fig. 3).
Hospital admissions
In Austria the vast majority of chemotherapies for
CRPC are given on an outpatient basis in urological
or oncological institutions. For reimbursement rea-
sons, these patients are admitted on a day case basis
and are included to the hospital admission statistics;
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Fig. 1 aOverall survival of
the total studycohort (n=
270). bFrequencydistribu-
tionof theremaining lifespan
spent in hospital care
Fig. 2 Overall survival stratifiedbypatient age
therefore, we have deleted all admissions for 24 h or
less from further analyses.
The mean length of hospital stay was 4.5 ± 4.8 days
(median 2 days). The duration of the hospital ad-
missions was as follows: 1–2 days 55.8%, 3–4 days
13.4%, 5–6 days 6.9%, 6–8 days 7.3%, 8–10 days 5.5%
and >10 days 11.1%. The patients in this series spent
a considerable time of their remaining life in hospital
care. Of all 270 patients only 19 (7%) were not hospi-
talized during their remaining life span. On the other
end of the spectrum 71 (26.2%) spent more than 50%
of their remaining life span in hospital care (Fig. 1b).
Discussion
The principal findings of this Austrian prescription
database analysis were (i) high adherence to AA, (ii)
high mortality within the first months of AA prescrip-
tion, (iii) 24% long-term survivors under AA and (iv)
high rate of hospitalization in patients under AA.
Prior to discussion, several pros and cons of our
approach need to be discussed. Strengths are: (i) the
population-based character of this database. The
WGKK is the biggest insurance company in Austria
(8.4 million insured persons) and it has 1.2 million
members in all socioeconomic classes, (ii) for decades
Austria has had a public and equal access healthcare
system with compulsory state health insurance com-
pany and (iii) long follow-up and complete survival
data due to matching with the Austrian death statis-
Fig. 3 Overall survival stratifiedbydurationofAA treatment
tics. The main limitation is the lack of any clinical
information (e.g. indications, previous chemotherapy,
staging and reason for drug discontinuation). Finally,
the data on hospital admissions have to be interpreted
in the context of the Austrian healthcare system.
Cancer treatment is evolving. Chronic oral admin-
istration transfers responsibility from the practitioner
to the patient, making adherence an important pa-
rameter in reducing the risk of treatment failure. Ad-
herence to medical treatment is a complex and multi-
faceted issue that can substantially alter the outcome
of therapy [6–10].
Outside randomized controlled trials (RCT) few
studies have reported on the adherence to AA. Smith
et al. [4] analyzed pharmacy claims of the Canadian
Saskatchewan Cancer Agency. All patients with at
least one AA prescription were eligible and a total of
86 patients were followed for a minimum of 6 months.
Optimal drug adherence was achieved in 82.6% of pa-
tients with 79.1% reaching a MPR of at least 90%. At
6 months the mean MPR was 89.6% (median 100%)
and after 12 months 86.6% (median 99.5%). Lafeuille
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et al. [5] studied this issue by analyzing two large-
scale US administrative healthcare claims databases.
The mean age of the patients was 72.2 years and the
mean MPR was 93% (median 98%). The mean MPR
in our series was 94.8 ± 11.9 (median 100%) with no
relevant impact of patient age in contrary to the study
by Grundmark et al. [6]. Taken together, these two
studies with a substantial number of analyzed pa-
tients indicate that the adherence to AA in a real-life
setting is satisfactory with median values exceeding
95%.
In contrast to the prescription database studies de-
scribed previously, this current one is unique with re-
spect to the availability of survival data. There is a ma-
jor concern that survival data generated by RCT or reg-
istries do not reflect the real life setting [11–16]. It has
been previously shown that eligibility to a chemother-
apy protocol represents per se a good prognostic fac-
tor [17]. In the pivotal phase III trial of AA in the
postchemotherapy setting de Bono et al. [18] reported
on a median survival of 14.8 months as compared to
11 months in our series. The median age of our pa-
tients, however, was 6 years older compared to the de
Bono et al. [18] trial. The maximum follow-up in our
study was considerable longer (38 months) as com-
pared to the pivotal phase III trial with 20 months.
There are a considerable number of long-term sur-
vivors. In our series, 24% of patients survived longer
than 20 months and 37% in the phase III trial. The
early mortality rate, however, was substantially higher
in our series. Within the first 6 months of AA treat-
ment 39% of our patients died as compared to only
15% in the de Bono et al. phase III trial [18]. These
data suggest that patient selection in real life is sub-
stantially less stringent than in a phase III trial. In
our series, patient age had a relevant impact on over-
all survival. In patients aged 46–76 years the median
survival was 17 months and thus longer than in the
pivotal RCT as compared to only 5 months in those
older than 76 years. Houede et al. [19] reported on
the long-term outcome of the AA temporary autho-
rization for use program in France: 306 patients with
a median age of 63 years were analyzed. The over-
all survival in this cohort after initiation of AA was
14.6 months, almost identical to the RCT and longer
than in our series. As expected, OS was correlated to
the duration of AA treatment, a similar phenomenon
was observed in our series (see Fig. 3).
The third aspect of this study was the analysis of
hospital admissions and length of hospitalization af-
ter initiation of AA. In our series, these patients spent
a considerable time of their remaining life in hospital
care. Only 7% were not hospitalized and one quarter
of patients (26.2%) spent more than 50% of their re-
maining life span in hospital care. These data have to
be interpreted in the context of the Austrian health-
care system, where admission to hospital care is lib-
eral and free of charge to the patient; furthermore,
there is no incentive to discharge patients as early as
possible. We could not identify a comparable analysis
with CRPC patients under chemotherapy and second-
line endocrine therapy in the literature.
According to Svensson et al. [20] patients were on
average 2 years older than those in the RCT, which is
partly in agreement with our study population, OS in
Swedish patients was the same like de Bono et al. [18]
(COU-AA-301 trial), in contrary to our results, and the
researchers concluded that the treated population and
treatment patterns, organization of healthcare, as well
as country setting could contribute to differences in
outcomes between the clinical trial and the real world
treatment, which could be an explanation for our OS
results in comparison to the randomized controlled
trials.
Outcomes of treatment in clinical practice can dif-
fer from outcomes in RCT with regard to the estimated
effectiveness and the estimated resource utilization.
Discrepancies in patient and physician behavior be-
tween the trial and the real world may have an impact
on outcome and treatment cost.
In clinical trials patients continued treatment un-
til documented progression while the real world ev-
idence study collected information on progression.
There is much interest in confirming whether the ef-
ficacy of AA demonstrated within the trial setting is
reproducible in routine clinical practice in a non-trial
setting and many differences should be taken in con-
sideration between both, such as the selection of pa-
tients and ethnic differences.
The OS in the study of Poon et al. [21] of
chemotherapy-naive patients was 18.1 months and
much shorter than that reported in the COU-AA-302
study (of 34.7 months) Ryan [16] and a higher propor-
tion of elderly patients, which is in agreement with
our study.
Limitations
The main limitation is the lack of any clinical informa-
tion (e.g. indications, previous chemotherapy, staging
and reason for drug discontinuation). Finally, the data
on hospital admissions have to be interpreted in the
context of the Austrian healthcare system where ad-
mission to hospital care is voluntary and free of charge
to the patient; furthermore, there is no incentive to
discharge patients as early as possible.
Conclusion
This Austrian prescription database allows some rele-
vant insights into the outcome of patients treated with
AA for CRPC in a real life setting. Drug adherence was
satisfactory and OS was shorter as compared to the
pivotal phase III trial. The high early mortality rate
in our series suggests poor patient selection in real
life. One quarter of patients experience long-term sur-
vival. The hospitalization rate within this cohort was
substantial.
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